Meeting
2016 ASCO Annual Meeting
Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer? Final analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).
Authors
Bernard M. Dubray
CRLCC Henri Becquerel, Rouen, France
Bernard M. Dubray , Julia Salleron , Stephane Gilles Guerif , Elisabeth Le Prise , Agnes Reynaud-Bougnoux , Jean-Michel Hannoun-Levi , Tan Dat Nguyen , Christophe Hennequin , Jacques Cretin , Maryse Fayolle-Campana , Jean-Leon Lagrange , Jean-Marc Bachaud , David Azria , Alain Grangirard , Pascal Pommier , Jean-Marc Simon , Muriel Habibian , Pierre Bey , Veronique Beckendorf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer–Local-Regional Disease
Clinical Trial Registration Number
EU-20503 / NCT00104741
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5021)
DOI
10.1200/JCO.2016.34.15_suppl.5021
Abstract #
5021
Poster Bd #
278
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).
First Author: B. M. Dubray
Poster
2023 ASCO Annual Meeting
Propensity score matched analysis of major adverse cardiac events in patients with localized prostate cancer receiving short term vs long term ADT.
First Author: Ye Yuan
Poster
2023 ASCO Genitourinary Cancers Symposium
5-Year result of single-institute cohort study in single-fraction HDR monotherapy for localised prostate cancer.
First Author: Imtiaz Ahmed
Poster
2023 ASCO Genitourinary Cancers Symposium
Biochemical disease control outcomes of stereotactic body radiation therapy (SBRT) or moderate hypo-fractionation (HFRT) for low- and intermediate-risk prostate cancer (PrCa): Retrospective analysis of 12 years of experience at two Canadian cancer centers.
First Author: Hsin-pei (Spencer) Hu